Nutex Health Appoints John G. Ruiz as CEO and Chairman
Ticker: NUTX · Form: 8-K · Filed: Apr 8, 2024 · CIK: 1479681
Sentiment: neutral
Topics: leadership-change, ceo-appointment, board-changes
Related Tickers: NUTX
TL;DR
Nutex Health just named John G. Ruiz as CEO & Chairman, replacing Michael J. McLain.
AI Summary
Nutex Health, Inc. announced on April 8, 2024, the appointment of John G. Ruiz as Chief Executive Officer and Chairman of the Board, effective immediately. Ruiz, who previously served as a director, will also continue his role as General Counsel. The company also reported the resignation of its previous CEO, Michael J. McLain, and a director, John L. Smith.
Why It Matters
The appointment of a new CEO and Chairman can signal a strategic shift or a renewed focus for the company, potentially impacting its future performance and investor outlook.
Risk Assessment
Risk Level: medium — Leadership changes can introduce uncertainty and potential shifts in strategy, which may affect the company's stability and future performance.
Key Players & Entities
- Nutex Health, Inc. (company) — Registrant
- John G. Ruiz (person) — Appointed CEO and Chairman of the Board
- Michael J. McLain (person) — Resigned CEO
- John L. Smith (person) — Resigned Director
- April 8, 2024 (date) — Effective date of appointments and resignations
FAQ
Who has been appointed as the new CEO and Chairman of Nutex Health, Inc.?
John G. Ruiz has been appointed as the new Chief Executive Officer and Chairman of the Board of Nutex Health, Inc.
When were these leadership changes effective?
The leadership changes were effective as of April 8, 2024.
Who has resigned from their positions at Nutex Health, Inc.?
Michael J. McLain (CEO) and John L. Smith (Director) have resigned from their positions.
What other role does John G. Ruiz hold within the company?
John G. Ruiz will continue to serve as the General Counsel of Nutex Health, Inc.
What was the previous name of Nutex Health, Inc.?
Nutex Health, Inc. was formerly known as Clinigence Holdings, Inc. until November 13, 2019.
Filing Stats: 845 words · 3 min read · ~3 pages · Grade level 11.4 · Accepted 2024-04-08 17:08:07
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value NUTX The NASDAQ Stock Mar
- $150,000 — oyee directors receive cash payments of $150,000 per year paid in monthly installments.
Filing Documents
- nutx-20240408x8k.htm (8-K) — 31KB
- 0001558370-24-004842.txt ( ) — 157KB
- nutx-20240408.xsd (EX-101.SCH) — 4KB
- nutx-20240408_def.xml (EX-101.DEF) — 3KB
- nutx-20240408_lab.xml (EX-101.LAB) — 17KB
- nutx-20240408_pre.xml (EX-101.PRE) — 11KB
- nutx-20240408x8k_htm.xml (XML) — 5KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description of Exhibit 104 Cover Page Interactive Data File (embedded within the Inline XBRL document SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: April 8, 2024 Nutex Health Inc. By: /s/ Jon C. Bates Jon C. Bates Chief Financial Officer